Skip to main content

Table 2 Baseline characteristics of the MDT and non-MDT groups, before and after PSM

From: The role of a multidisciplinary team in the management of portal hypertension

 

Global Population (n = 528)

Propensity Score Matching (n = 169)

MDT (n = 86)

Non-MDT (n = 442)

P-value

MDT (n = 58)

Non-MDT (n = 111)

P-value

General Characteristics

Gender

 Male

59 (68.6%)

292 (66.1%)

0.74

39 (67.2%)

88 (79.3%)

0.275

 Female

27 (31.4%)

150 (33.9%)

 

19 (32.8%)

23 (20.7%)

Age (years)

52.91 ± 13.08

53.63 ± 10.55

0.579

51.76 ± 12.39

50.68 ± 11.73

0.089

Child Pugh Classification

 Class A

44 (51.2%)

224 (50.7%)

0.371

28 (48.3%)

55 (49.5%)

0.761

 Class B

41 (47.7%)

199 (45%)

 

29 (50.0%)

52 (46.8%)

 Class C

1 (1.2%)

19 (4.3%)

 

1 (1.7%)

4 (3.6%)

MELD Score

7.04 ± 4.59

6.57 ± 4.23

0.359

7.51 ± 4.09

7.22 ± 3.78

0.64

Etiology of Portal Hypertension

 Viral Hepatitis

46 (53.5%)

254 (57.5%)

0.027

35 (60.3%)

60 (54.1%)

0.894

 Alcohol

4 (4.7%)

40 (9%)

 

2 (3.4%)

8 (7.2%)

 AIH/PBC

5 (5.8%)

54 (12.2%)

 

4 (6.9%)

7 (6.3%)

 Schistosomiasis

9 (10.5%)

19 (4.3%)

 

6 (10.3%)

10 (9.0%)

 Others

19 (22.1%)

66 (14.9)

 

10 (17.2%)

23 (20.7%)

 Mixed

3 (3.5%)

9 (2%)

 

1 (1.7%)

3 (2.7%)

Received Previous Treatment

37 (43.0%)

95 (21.5%)

< 0.001

30 (51.7%)

53 (47.7%)

0.742

Concurrent Conditions

Portal Venous Thrombosis

0.841

 Absent

53 (61.6%)

351 (79.4%)

0.005

52 (89.7%)

102 (91.9%)

 Present

33 (38.4%)

91 (20.6%)

 

6 (10.3%)

9 (8.1%)

Hepatic Cellular Carcinoma

0.886

 Absent

77 (89.5%)

413 (93.4%)

0.292

50 (86.2%)

98 (88.3%)

 Present

9 (10.5%)

29 (6.6%)

 

8 (13.8%)

13 (11.7%)

Endoscopic Examination

Gastroesophageal Classification

 EV

16 (18.6%)

133 (30.1%)

< 0.001

14 (24.1%)

35 (31.5%)

0.158

 GOV Type 1

23 (26.7%)

275 (62.2%)

19 (32.8%)

46 (41.4%)

 GOV Type 2

30 (34.9%)

18 (4.1%)

16 (27.6%)

16 (14.4%)

 IGV Type 1

17 (19.8%)

16 (3.6%)

9 (15.5%)

14 (12.6%)

Treatment Received

 Pharmacological Treatment

12 (14%)

8 (1.8%)

< 0.001

8 (13.8%)

8 (7.2%)

0.004

 Endoscopy

28 (32.6%)

375 (84.8%)

26 (44.8%)

68 (61.3%)

 Surgery

7 (8.1%)

48 (10.9%)

7 (12.1%)

24 (21.6%)

 Interventional Radiology

37 (43%)

8 (1.8%)

15 (25.9%)

8 (7.2%)

 Combined Therapy

2 (2.3%)

3 (0.7%)

2 (3.4%)

3 (2.7%)